Research Paper Volume 12, Issue 14 pp 14897—14917

Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson’s disease models through activating the MEF2-PGC1α and BDNF/CREB pathways

class="figure-viewer-img"

Figure 2.

T-006 improves motor behavior and prevents dopaminergic neurodegeneration in rats subjected to 6-OHDA. (A) Schedule for T-006 treatment of a progressive 6-OHDA rat PD model. (B) The changes of body weight in different groups (n=12-16 per group). (C) Turns initiated by apomorphine-induced 6-OHDA rats. (D) Time spent on the rotarod. (E) Distance travelled (cm) in open field. (F) Discrimination index in new objective test. (G) Immunohistochemistry for TH in SN. (H) Stereological counting of TH-positive DA neurons from SN. (I) Representative Western blots illustrating the expression of TH in SN. (J) Densitometric analysis of TH/β-actin of treatment with T-006 at the indicated concentrations in SN. (KM) Striatal dopamine and its metabolites DOPAC and HVA were analyzed by electrochemical HPLC with 6 to 8 mice per group. The results are shown as the mean±SEM. #P<0.05, ##P<0.01, ###P<0.001 vs. sham group, and *P<0.05, **P<0.01 and ***P<0.001vs. 6-OHDA group.